
Safety and efficacy in pediatric patients have not been Exercise caution when administering to a nursing woman. It is not known if this medication is excreted in breast

Potential benefit justifies the potential risk to the fetus. Intraocular solution, USP) should be used during pregnancy only if the There are no adequate and well-controlled studies in pregnant women. Studies in animals to evaluate the carcinogenic potential

The vial stopper contains natural rubber (latex) which Spasm, urinary tract obstruction and Parkinson's disease. With acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, G.I. Intraocular carbachol 0.01% should be used with caution in patients DRUG INTERACTIONSįor single-dose intraocular use only. Vision blurred, visual impairment, and vomiting. Inflammation, eye pain, intraocular pressure increased, ocular hyperemia, Reporting, possible causal connection to MIOSTAT, or a combination of theseįactors, include: corneal edema, drug effect prolonged ( miosis), eye The reactions, which haveīeen chosen for inclusion due to either their seriousness, frequency of Unknown size, estimates of frequency cannot be made. Because they are reported voluntarily from a population of The following additional reactions have been identifiedĭuring post-approval use of MIOSTAT (carbachol intraocular solution, USP) inĬlinical practice. Topical or systemic application of carbachol. Urinary bladder, and headache have been reported with Revised: Mar 2016 SLIDESHOW Digestive Disorders: Common Misconceptions See SlideshowĬlouding, persistent bullous keratopathy, retinal detachment and postoperative iritis following cataract extraction have been reported.Įffects such as flushing, sweating, epigastric distress, abdominal cramps, Laboratories, Inc., Fort Worth, Texas 76134 USA. Stopper and aluminum seal packaged twelve to a carton. In a 2.0 mL glass vial with a 1.5 mL fill, grey butyl Miosis is usually maximal within two to five minutes after It may be instilled before or after securing Milliliter should be gently instilled into the anterior chamber for the Withdraw the contents into a dry sterile syringe, and replace the needle with anĪtraumatic cannula prior to intraocular instillation. Package by peeling the backing paper and dropping the vial onto a sterile tray. DOSAGE AND ADMINISTRATIONĪseptically remove the sterile vial from the blister Of intraocular pressure elevation in the first 24 hours after cataract surgery. InĪddition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity Intraocular use for obtaining miosis during surgery. Inactives: sodium chloride 0.64%, potassium chloride 0.075%, calcium chloride dehydrate 0.048%, magnesium chloride hexahydrate 0.03%, sodium acetate trihydrate 0.39%, sodium citrate dehydrate 0.17%, sodium hydroxide and/or hydrochloric acid (to adjust pH) and Water for Injection. The active ingredient is represented by the chemical structure:Ĭhemical name: Ethanaminium, 2-N,N,Ntrimethyl-, chloride.Įach mL contains: Active: carbachol 0.01%. MIOSTAT® (carbachol intraocular solution, USP) is a sterile balanced salt solution of carbachol for intraocular injection. You may report side effects to FDA at 1-80.

For more information, ask your doctor or pharmacist.Ĭall your doctor for medical advice about side effects. These are not all the possible side effects of Miostat. Tell the doctor if you have any side effect that bothers you or that does not go away. flushing (warmth, redness, or tingly feeling),.The most common side effects of Miostat include: Get medical help right away, if you have any of the symptoms listed above.

swelling of your face, lips, tongue, or throat,.Miostat may cause serious side effects including: What are the possible side effects of Miostat? Miostat belongs to a class of drugs called Miotics, Direct-Acting Antiglaucoma, Miotics. Miostat may be used alone or with other medications. Miostat is a prescription medicine used to treat the symptoms of Glaucoma and Inhibition of Perioperative Intraocular Pressure.
